Close Menu

NEW YORK (GenomeWeb) – BioGx announced today that Switzerland's AxonLab will distribute assay products from BioGx's European-based subsidiary in multiple European countries.

As part of the multi-year collaboration, AxonLab will work with a Netherlands-based subsidiary of Birmingham, Alabama-based BioGx to distribute its products to the majority of Central Europe, including Austria, Belgium, the Czech Republic, Germany, Slovenia, Switzerland, and Croatia. Distribution will include all of BioGx's CE-IVD product line, as well as laboratory-use-only products.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.